May 11, 2020 4:05pm EDT Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
May 04, 2020 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020
Apr 28, 2020 7:00am EDT Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference
Mar 31, 2020 7:00am EDT Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs
Mar 09, 2020 6:30am EDT Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Mar 05, 2020 7:00am EST Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®
Mar 04, 2020 7:00am EST Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board
Feb 24, 2020 4:15pm EST Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020
Feb 19, 2020 7:00am EST Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
